These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Verrica Pharmaceuticals (VRCA), 618% surge in interest Verona Pharma
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Verrica Pharmaceuticals (VRCA), 618% surge in interest Verona Pharma
Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says it has
Takeda Pharmaceutical Company ( ($TAK) ) has released its Q2 earnings. Here is a breakdown of the information Takeda Pharmaceutical Company presented to its investors. Takeda Pharmaceutical Company Limited, a
Hutchmed (HCM) announced that it will receive a $20M milestone payment from its partner Takeda (TAK), triggered by reaching over $200M in sales of Fruzaqla for metastatic colorectal cancer, or
Takeda Pharmaceutical Company (TAK) is scheduled to report 2nd quarter earnings on 10/31/2024. Regarding Q2 estimates, Wall Street analysts expect Takeda Pharmaceutical Company to post earnings of $0.12 per share.